TEM8 targeted cancer therapy

Arthur E. Frankel, Carol Carter, Shu Ru Kuo, Jung Hee Woo, Jeremy Mauldin, Jen Sing Liu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Tumor growth depends upon access to host blood vessels. Many steps in tumor angiogenesis have been defined including tumor cell hypoxia, tumor cell secretion of pro-angiogenic growth factors, receptor activation on host endothelium and stroma, and establishment of new blood vessels feeding the tumor mass. Inhibitors for some of these steps have been synthesized and tested clinically. While modest improvements in response, progression-free survival and overall survival have been observed in metastatic colorectal carcinoma, non-small cell lung carcinoma, breast carcinoma, renal cell carcinoma, and glioblastoma, almost all patients ultimately relapse and die from metastatic disease. Explanations for the limited effects of anti-angiogenesis therapy include lack of activity on all the parallel angiogenic pathways, non-specific toxicities of some of the agents, induction of a pro-metastatic phenotype by the enhanced hypoxia from therapy, and lack of effect on already established tumor blood vessels. One solution is to directly attack the tumor vasculature rather than inhibit tumor vessel formation. The flavonoid ASA404 and the tubulin-binder combretastatin A-4 phosphate directly damage tumor endothelium by different mechanisms. Both compounds have shown minimal single agent disease activity and produce cardiac ischemia in clinical trials. Recently, ligand-directed vascular disrupting agents have been synthesized and tested. A promising member of this class of therapeutics targets the tumor endothelial marker-8 (TEM8). Anti-TEM8 antibody drug conjugate may facilitate selective destruction of tumor blood vessels yielding enhanced anti-cancer efficacy and reduced normal tissue toxicities. Advances in this field are described which should lead to clinical studies of TEM8 targeted cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)983-992
Number of pages10
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume11
Issue number10
StatePublished - Dec 2011

Fingerprint

Tumor Biomarkers
Vascular Tissue Neoplasms
Neoplasms
vadimezan
Therapeutics
Endothelium
Blood Vessels
Growth Factor Receptors
Angiogenesis Inducing Agents
Tubulin
Glioblastoma
Renal Cell Carcinoma
Flavonoids
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Colorectal Neoplasms
Ischemia
Phosphates
Clinical Trials
Breast Neoplasms

Keywords

  • Angiogenesis
  • Antibody drug conjugate
  • Ligand-directed vascular disrupting agents
  • Tem8

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Cite this

Frankel, A. E., Carter, C., Kuo, S. R., Woo, J. H., Mauldin, J., & Liu, J. S. (2011). TEM8 targeted cancer therapy. Anti-Cancer Agents in Medicinal Chemistry, 11(10), 983-992.

TEM8 targeted cancer therapy. / Frankel, Arthur E.; Carter, Carol; Kuo, Shu Ru; Woo, Jung Hee; Mauldin, Jeremy; Liu, Jen Sing.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 10, 12.2011, p. 983-992.

Research output: Contribution to journalArticle

Frankel, AE, Carter, C, Kuo, SR, Woo, JH, Mauldin, J & Liu, JS 2011, 'TEM8 targeted cancer therapy', Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 10, pp. 983-992.
Frankel AE, Carter C, Kuo SR, Woo JH, Mauldin J, Liu JS. TEM8 targeted cancer therapy. Anti-Cancer Agents in Medicinal Chemistry. 2011 Dec;11(10):983-992.
Frankel, Arthur E. ; Carter, Carol ; Kuo, Shu Ru ; Woo, Jung Hee ; Mauldin, Jeremy ; Liu, Jen Sing. / TEM8 targeted cancer therapy. In: Anti-Cancer Agents in Medicinal Chemistry. 2011 ; Vol. 11, No. 10. pp. 983-992.
@article{da44b0c582da46f7a1d1ad72ce3aa24c,
title = "TEM8 targeted cancer therapy",
abstract = "Tumor growth depends upon access to host blood vessels. Many steps in tumor angiogenesis have been defined including tumor cell hypoxia, tumor cell secretion of pro-angiogenic growth factors, receptor activation on host endothelium and stroma, and establishment of new blood vessels feeding the tumor mass. Inhibitors for some of these steps have been synthesized and tested clinically. While modest improvements in response, progression-free survival and overall survival have been observed in metastatic colorectal carcinoma, non-small cell lung carcinoma, breast carcinoma, renal cell carcinoma, and glioblastoma, almost all patients ultimately relapse and die from metastatic disease. Explanations for the limited effects of anti-angiogenesis therapy include lack of activity on all the parallel angiogenic pathways, non-specific toxicities of some of the agents, induction of a pro-metastatic phenotype by the enhanced hypoxia from therapy, and lack of effect on already established tumor blood vessels. One solution is to directly attack the tumor vasculature rather than inhibit tumor vessel formation. The flavonoid ASA404 and the tubulin-binder combretastatin A-4 phosphate directly damage tumor endothelium by different mechanisms. Both compounds have shown minimal single agent disease activity and produce cardiac ischemia in clinical trials. Recently, ligand-directed vascular disrupting agents have been synthesized and tested. A promising member of this class of therapeutics targets the tumor endothelial marker-8 (TEM8). Anti-TEM8 antibody drug conjugate may facilitate selective destruction of tumor blood vessels yielding enhanced anti-cancer efficacy and reduced normal tissue toxicities. Advances in this field are described which should lead to clinical studies of TEM8 targeted cancer therapeutics.",
keywords = "Angiogenesis, Antibody drug conjugate, Ligand-directed vascular disrupting agents, Tem8",
author = "Frankel, {Arthur E.} and Carol Carter and Kuo, {Shu Ru} and Woo, {Jung Hee} and Jeremy Mauldin and Liu, {Jen Sing}",
year = "2011",
month = "12",
language = "English (US)",
volume = "11",
pages = "983--992",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - TEM8 targeted cancer therapy

AU - Frankel, Arthur E.

AU - Carter, Carol

AU - Kuo, Shu Ru

AU - Woo, Jung Hee

AU - Mauldin, Jeremy

AU - Liu, Jen Sing

PY - 2011/12

Y1 - 2011/12

N2 - Tumor growth depends upon access to host blood vessels. Many steps in tumor angiogenesis have been defined including tumor cell hypoxia, tumor cell secretion of pro-angiogenic growth factors, receptor activation on host endothelium and stroma, and establishment of new blood vessels feeding the tumor mass. Inhibitors for some of these steps have been synthesized and tested clinically. While modest improvements in response, progression-free survival and overall survival have been observed in metastatic colorectal carcinoma, non-small cell lung carcinoma, breast carcinoma, renal cell carcinoma, and glioblastoma, almost all patients ultimately relapse and die from metastatic disease. Explanations for the limited effects of anti-angiogenesis therapy include lack of activity on all the parallel angiogenic pathways, non-specific toxicities of some of the agents, induction of a pro-metastatic phenotype by the enhanced hypoxia from therapy, and lack of effect on already established tumor blood vessels. One solution is to directly attack the tumor vasculature rather than inhibit tumor vessel formation. The flavonoid ASA404 and the tubulin-binder combretastatin A-4 phosphate directly damage tumor endothelium by different mechanisms. Both compounds have shown minimal single agent disease activity and produce cardiac ischemia in clinical trials. Recently, ligand-directed vascular disrupting agents have been synthesized and tested. A promising member of this class of therapeutics targets the tumor endothelial marker-8 (TEM8). Anti-TEM8 antibody drug conjugate may facilitate selective destruction of tumor blood vessels yielding enhanced anti-cancer efficacy and reduced normal tissue toxicities. Advances in this field are described which should lead to clinical studies of TEM8 targeted cancer therapeutics.

AB - Tumor growth depends upon access to host blood vessels. Many steps in tumor angiogenesis have been defined including tumor cell hypoxia, tumor cell secretion of pro-angiogenic growth factors, receptor activation on host endothelium and stroma, and establishment of new blood vessels feeding the tumor mass. Inhibitors for some of these steps have been synthesized and tested clinically. While modest improvements in response, progression-free survival and overall survival have been observed in metastatic colorectal carcinoma, non-small cell lung carcinoma, breast carcinoma, renal cell carcinoma, and glioblastoma, almost all patients ultimately relapse and die from metastatic disease. Explanations for the limited effects of anti-angiogenesis therapy include lack of activity on all the parallel angiogenic pathways, non-specific toxicities of some of the agents, induction of a pro-metastatic phenotype by the enhanced hypoxia from therapy, and lack of effect on already established tumor blood vessels. One solution is to directly attack the tumor vasculature rather than inhibit tumor vessel formation. The flavonoid ASA404 and the tubulin-binder combretastatin A-4 phosphate directly damage tumor endothelium by different mechanisms. Both compounds have shown minimal single agent disease activity and produce cardiac ischemia in clinical trials. Recently, ligand-directed vascular disrupting agents have been synthesized and tested. A promising member of this class of therapeutics targets the tumor endothelial marker-8 (TEM8). Anti-TEM8 antibody drug conjugate may facilitate selective destruction of tumor blood vessels yielding enhanced anti-cancer efficacy and reduced normal tissue toxicities. Advances in this field are described which should lead to clinical studies of TEM8 targeted cancer therapeutics.

KW - Angiogenesis

KW - Antibody drug conjugate

KW - Ligand-directed vascular disrupting agents

KW - Tem8

UR - http://www.scopus.com/inward/record.url?scp=80055110887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055110887&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 983

EP - 992

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 10

ER -